» Articles » PMID: 15326293

Enhanced SIV Replication and Accelerated Progression to AIDS in Macaques Primed to Mount a CD4 T Cell Response to the SIV Envelope Protein

Overview
Specialty Science
Date 2004 Aug 25
PMID 15326293
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Given the dual role of CD4 T cells as both immune effectors and targets for HIV infection, the balance of CD4 versus CD8 T cell-mediated responses induced by candidate AIDS vaccines may be critical in determining postvaccination infection outcomes. An attenuated recombinant varicella-zoster virus vaccine expressing the simian immunodeficiency virus (SIV) envelope (Env) elicited nonneutralizing Env-binding antibodies and little if any cytotoxic T lymphocyte responses in rhesus macaques (Macaca mulatta). After challenge with SIV, Env vaccinees manifested increased levels of SIV replication, more rapid CD4 depletion, and accelerated progression to AIDS compared with controls. Enhanced SIV replication correlated with increased CD4 T cell proliferation soon after SIV challenge, apparently the result of an anamnestic response to SIV antigens. Thus activation of virus-specific CD4 T cells at the time of exposure to a CD4 T cell-tropic lentivirus, in the absence of an effective CD8 response, may enhance virus replication and disease. These data suggest suggest that candidate AIDS vaccines may not simply be either efficacious or neutral; they may also have the potential to be harmful.

Citing Articles

Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells.

Zimmermann J, van Haren S, Diray-Arce J, Adriawan I, Worzner K, Krog R NPJ Vaccines. 2023; 8(1):189.

PMID: 38135685 PMC: 10746746. DOI: 10.1038/s41541-023-00781-0.


A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.

Cohen K, De Rosa S, Fulp W, deCamp A, Fiore-Gartland A, Mahoney C Sci Transl Med. 2023; 15(697):eadf3309.

PMID: 37224227 PMC: 11036875. DOI: 10.1126/scitranslmed.adf3309.


HIV T-cell immunogen design and delivery.

Brander C, Hartigan-OConnor D Curr Opin HIV AIDS. 2022; 17(6):333-337.

PMID: 36165078 PMC: 9530002. DOI: 10.1097/COH.0000000000000765.


Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.

Bigay J, Le Grand R, Martinon F, Maisonnasse P Front Microbiol. 2022; 13:932408.

PMID: 36033843 PMC: 9399815. DOI: 10.3389/fmicb.2022.932408.


CD4 T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help.

Klessing S, Temchura V, Tannig P, Peter A, Christensen D, Lang R Vaccines (Basel). 2020; 8(4).

PMID: 33066267 PMC: 7711721. DOI: 10.3390/vaccines8040604.


References
1.
Giannecchini S, Isola P, Sichi O, Matteucci D, Pistello M, Zaccaro L . AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol. 2002; 76(14):6882-92. PMC: 136316. DOI: 10.1128/jvi.76.14.6882-6892.2002. View

2.
Raabe M, Issel C, Montelaro R . In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology. 1999; 259(2):416-27. DOI: 10.1006/viro.1999.9772. View

3.
Chakrabarti L, Lewin S, Zhang L, Gettie A, Luckay A, Martin L . Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol. 2000; 74(3):1209-23. PMC: 111455. DOI: 10.1128/jvi.74.3.1209-1223.2000. View

4.
Lifson J, Rossio J, Arnaout R, Li L, Parks T, Schneider D . Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol. 2000; 74(6):2584-93. PMC: 111746. DOI: 10.1128/jvi.74.6.2584-2593.2000. View

5.
Ourmanov I, Brown C, Moss B, Carroll M, Wyatt L, Pletneva L . Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol. 2000; 74(6):2740-51. PMC: 111764. DOI: 10.1128/jvi.74.6.2740-2751.2000. View